Invectys has announced success with its therapeutic vaccine INVAC-1 that shows ‘excellent innocuity' and high tolerance in patients. During the third stage of the ongoing phase I clinical trial, INVAC-1 was administered at the highest dose level planned in the trial without the slightest problem of toxicity or tolerance, so showing a ‘superb’ safety profile.
INVAC-1 is an innovative vaccine specifically targeting the enzyme telomerase that is over expressed in the large majority of cancerous cells and which plays an essential role in their uncontrolled proliferation.
Tolerance and encouraging immunological results
“This success comes on the back of very encouraging initial results in terms of immunological responses in treated patients and opens up the way to treatment of an extension cohort of new patients that will tie up the phase I trial with the optimal dose. It allows us to plan the phase II trial with confidence” said Pierre Langlade Demoyen, CEO and co-founder of Invectys. “For many patients we noted a stabilization of disease following several cycles of treatment, which presages well the therapeutic potential of our therapeutic vaccine. With INVAC-1, we hope to provide new treatment perspectives for patients with cancer.”
These promising results follow the very recent announcement of an additional 7 million euros capital raise from Invectys’ historic investors. It brings to 17 million euros the sum raised by the company from this group of family offices, business angels and private investors who have accompanied Invectys since its creation in 2010.
